Q2 2016 13F Holders as of 6/30/2016
-
Type / Class
-
Debt / NOTE 4.500% 7/1
-
Number of holders
-
12
-
Total principal
-
53.2M
-
Principal change
-
-62.2M
-
Total reported value, excl. options
-
$59.2M
-
Value change
-
-$88M
-
Number of buys
-
3
-
Number of sells
-
-7
-
Price
-
$1.12
Significant Holders of MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 as of Q2 2016
12 filings reported holding 590328AA8 - MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 as of Q2 2016.
MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 has 12 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $53.2M of principal
.
Largest 10 bondholders include LAZARD ASSET MANAGEMENT LLC ($16M of principal), WOLVERINE ASSET MANAGEMENT LLC ($12.7M of principal), JPMORGAN CHASE & CO ($7.12M of principal), Polar Capital LLP ($4.24M of principal), TANG CAPITAL MANAGEMENT LLC ($3.5M of principal), PUTNAM INVESTMENTS LLC ($2.94M of principal), AMERIPRISE FINANCIAL INC ($2.32M of principal), Tekla Capital Management LLC ($1.49M of principal), PALISADE CAPITAL MANAGEMENT LLC/NJ ($1.41M of principal), and Polygon Management Ltd. ($1M of principal).
This table shows the top 12 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.